Haemophilia · 2008 · 32 citations · 22 references
MedicineHematologyPharmacologyClinical ImmunologyHemostasisInflammationCoagulation AbnormalitiesPlatelet AdhesionPlatelet AggregationPlatelet PhysiologyThrombosisVon Willebrand DiseaseAnti-inflammatory ActivityAnti-inflammatory ResponseFactor Viii ActivationFactor Viii AlterationsVon Willebrand Factor AntigenVon Willebrand Factor DisordersVon Willebrand Factor FunctionVon Willebrand Factor-mediated Adhesion
von Willebrand factor (VWF) is a multimeric glycoprotein that mediates platelet adhesion and is decreased in von Willebrand disease (VWD). 1-8 deamino-d-arginine vasopressin (DDAVP), the most common treatment for VWD, is limited by tachyphylaxis and inconvenience, and in 20% of the patients, unresponsiveness. Recombinant human interleukin-11 (rhIL-11), a gp-130 signalling cytokine with haematopoietic and anti-inflammatory activity, increases VWF antigen and its activity in heterozygous VWF(+/-) mice and dogs. To determine the biological efficacy and safety of rhIL-11 in non-bleeding human subjects with mild VWD, we conducted a phase II prospective open-label trial of rhIL-11 at 10, 25 and 50 mug kg(-1) subcutaneously (s.c.), given daily for 7 days in nine subjects with mild VWD. VWF and factor VIII (FVIII) levels increased gradually and progressively after s.c. rhIL-11, which was sustained through 7 days of dosing to 1.5- to 3-fold over baseline. Following intravenous DDAVP, 0.3 mug kg(-1), on day 7 there was a further boost in VWF and FVIII levels, suggesting that the mechanism of rhIL-11 differs from that of DDAVP. Platelet VWF mRNA expression measured by quantitative PCR increased from two- to eightfold over baseline, suggesting that the mechanism of rhIL-11 effect may be upregulation of VWF mRNA. VWF and FVIII levels returned to baseline by day 14. rhIL-11 was well tolerated with less than grade-1 hypertension, hypokalaemia and fluid retention. Recombinant IL-11 increases VWF levels in humans with mild VWD, justifying future clinical trials to determine its potential in preventing or reducing bleeding in this patient population.
22
Epidemiological investigation of the prevalence of von Willebrand's disease
F Rodeghiero, Giancarlo Castaman, E Dini · Blood · 1987 · 1K citations · Full text
Medicine, Health Sciences, Pathology +11
Impact, Diagnosis and Treatment of von Willebrand Disease
J. Evan Sadler, Erik Berntorp, Victor Boulyjenkov et al. · Thrombosis and Haemostasis · 2000 · 503 citations
Anne Goodeve, Jeroen Eikenboom, Giancarlo Castaman et al. · Blood · 2006 · 400 citations · Full text